Adimab, LLC, a leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced that seven new partner programs entered clinical development in 2022. These programs include collaborations with Biotheus, Dragonfly, Innovent, Surface Oncology, and a program supported by the Gates Foundation, bringing the total number of Adimab partner programs in clinical trials to 62.
The most advanced program from Adimab’s platform is Tyvyt® (Sintilimab), currently marketed in China by Innovent. Additionally, partners have filed for BLA approval on three programs, with another three in pivotal trials.
Guy Van Meter, Chief Business Officer of Adimab, stated, "Over the last five years alone, partners have initiated clinical trials for 52 new programs. This progress validates our strategy implemented over the last 15 years." Philip T. Chase, Chief Executive Officer, emphasized Adimab's focus on supporting partners' development and commercialization efforts and reinvesting in technology and expertise.
Adimab's technologies include antibody discovery in IgG and single domain formats, engineering capabilities for optimizing antibodies, and extensive bispecific and multispecific capabilities. The company has developed proprietary workflows for complex targets, such as GPCRs and ion channels, to generate specific antibodies.
Since 2009, Adimab has partnered with over 105 pharmaceutical and biotechnology companies, generating more than 475 therapeutic programs and over 60 clinical programs. Adimab's integrated platform offers speed and diversity in antibody discovery, enabling partners to expand their biologics pipelines effectively.
